ANVS — Annovis Bio Balance Sheet
0.000.00%
Last trade - 00:00- $30.59m
- $20.04m
Annual balance sheet for Annovis Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 8.07 | 45.7 | 28.4 | 5.75 | 10.6 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 8.12 | 46 | 36 | 10.2 | 13.9 |
| Total Assets | 8.12 | 46 | 36 | 10.2 | 13.9 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.578 | 1.51 | 7.7 | 4.28 | 3.88 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.578 | 1.51 | 7.7 | 18 | 4.62 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 7.54 | 44.5 | 28.3 | -7.75 | 9.31 |
| Total Liabilities & Shareholders' Equity | 8.12 | 46 | 36 | 10.2 | 13.9 |
| Total Common Shares Outstanding |